Novonesis
World leader in biological solutions — formed Jan 2024 from Novozymes + Chr. Hansen merger; enzyme and microbial platform for food, feed, pharma, industrial biotech; 2025 organic growth +7%, EBITDA margin 37.1%; SE Asia production facility acquired April 2026.
- Country
- Denmark
- Revenue
- DKK 27B
- Employees
- ~10,000 emp
ISO 9001
ISO 14001
Halal
Kosher
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| agri-inputs-biocontrol | ✓ | ✓ | — | ✓ |
| agri-tech-precision | ✓ | ✓ | — | ✓ |
| bioremediation | ✓ | ✓ | ✓ | ✓ |
| cellulose-lignin | ✓ | ✓ | — | ✓ |
| crop-biotech | ✓ | ✓ | ✓ | ✓ |
| enzymes-biocatalysis | ✓ | ✓ | ✓ | ✓ |
| fibers-textiles | ✓ | ✓ | — | ✓ |
| food-alt-protein | ✓ | ✓ | ✓ | ✓ |
| genome-engineering | ✓ | ✓ | — | ✓ |
| regenerative-personalized | ✓ | ✓ | — | ✓ |
Regulatorsfdaefsaepamoa-chinanmpareachemaademeusda-aphis
Technologies
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.